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Objectives: We report the incidence of tuberculosis
(TB) across certolizumab pegol (CZP) clinical trials in
rheumatoid arthritis (RA), psoriasis, psoriatic arthritis
(PsA) and axial spondyloarthritis (axSpA), before and
after the introduction of stricter TB screening.
Methods: TB incidence rates (IRs) were assessed and
stratified according to screening guidelines used at the
time of CZP trials. Before 2007 (original trials), purified
protein derivative (PPD) tuberculin skin test positivity
varied according to local standards (induration ≥5 up
to ≥20 mm). Since 2007, all CZP trial protocols have
been amended, including trials spanning (intermediate)
and initiated after 2007 (current), mandating that any
patient with PPD≥5 mm receives treatment for latent
TB infection (LTBI). All cases of suspected TB or
PPD≥5 mm, in pooled data from 5402 CZP patients
across all CZP trials up to 2012, underwent blinded
central review by independent experts.
Results: 44 TB cases were confirmed in pooled CZP
RA trials (IR 0.47/100PY, patient-years) with no cases
in Japanese RA trials ( J-RAPID, HIKARI). Single TB
cases were confirmed in psoriasis and axSpA trials
(RAPID-axSpA), and no cases in the PsA trial (RAPID-
PsA). IR of TB was 0.51/100PY across original or
intermediate RA trials and 0.18/100PY in current trials.
The majority of TB cases in RA occurred in Eastern (IR
1.02/100PY) and Central Europe (IR 0.58/100PY). Of
242/370 PPD≥5 mm patients who received 9 months
isoniazid (INH) treatment for latent TB infection (LTBI),
none developed TB, versus 7.8% of 128 untreated
PPD≥5 mm patients.
Conclusions: Implementation of more stringent LTBI
screening, plus treatment for LTBI, reduced the IR of
TB, even when INH was administered after starting CZP
therapy.
INTRODUCTION
Antitumour necrosis factors (anti-TNFs) have
provided a major breakthrough in the
treatment of chronic inflammatory diseases but
are associated with an increased risk of oppor-
tunistic infections, including active tuberculosis
(TB).1 2 The onset of TB soon after initiation
of anti-TNF therapy indicates the probable
reactivation of latent TB infection (LTBI), while
TB appearing after several months or more of
continuous exposure to anti-TNF is likely to
arise due to a new infection.2–4 Reports suggest
that the incidence of TB in patients treated
with biologics has decreased over the past
decade thanks to screening of LTBI, as recom-
mended in several countries.5 However, the risk
of active TB (particularly non-pulmonary TB)
associated with anti-TNFs1 2 4 and underlying
inflammatory diseases5–7 remains an important
concern. Thus, patients being considered for
anti-TNF therapy should undergo initial screen-
ing for LTBI, and regular screening for TB
infection should be performed during
Key messages
What is already known on this subject?
▸ Antitumour necrosis factors (anti-TNFs) are
associated with an increased risk of opportunis-
tic infections, including active tuberculosis (TB).
What might this study add?
▸ Using a strict purified protein derivative (PPD)
cut-off of ≥5 mm induration, as well as a TB
questionnaire, may reduce the incidence of TB
in patients receiving anti-TNF therapy.
How might this impact on clinical practice?
▸ Antibiotic treatment for latent TB infection (LTBI)
at screening, or in patients already on anti-TNF
therapy if a history of PPD ≥5 mm is documen-
ted, decreases the incidence of TB in patients
receiving anti-TNF therapy.
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anti-TNF treatment if patients are living in, or have travelled
to, TB endemic regions. However, the benefits of repeat
screening in TB endemic regions are debatable8 and the
perfect approach for screening patients with anti-TNF has
not yet been resolved, with different strategies being used to
try to identify patients at risk of developing TB.
Prior to 2007, certolizumab pegol (CZP) trials screened
for TB by a purified protein derivative (PPD) tuberculin
skin test were evaluated according to the respective
national guidelines of the recruiting centre. The cut-off
value for positivity varied widely (from ≥5 up to ≥20 mm
induration), particularly in countries with higher bacillus
Calmette-Guérin (BCG) vaccination rates.9 10
In 2007, the WHO introduced stricter practical guide-
lines to reduce the risk of TB in patients starting anti-TNF
treatment and to help identify those at increased risk of
developing TB (PPD test results ≥5 mm were considered
positive).11 12 Similar screening recommendations have
since been introduced by several national rheumatology
societies to reduce the risk of TB infection in patients with
immune-mediated inflammatory disease (IMID).13–18 In
response to an increasing number of TB cases, mainly
from high TB incidence countries, and WHO recommen-
dations for more stringent TB screening, CZP trial proto-
cols were amended in 2007;11 12 mandating that any
patient with PPD ≥5 mm should begin 9 months isoniazid
(INH) treatment for LTBI. This included patients already
receiving CZP, even without any signs or symptoms consid-
ered to be TB-related. Patient TB questionnaires were also
administered, every 6 months, to increase patient/investi-
gator awareness of the symptoms and risk factors for TB
(figure 1).
CZP is approved for the treatment of adult patients
with moderate-to-severe RA, psoriatic arthritis (PsA),
axial spondyloarthritis (axSpA; including ankylosing
spondylitis) and Crohn’s disease.19 20 This paper reports
the incidence rate (IR) of TB during long-term CZP
treatment across indications (RA, psoriasis, PsA and
axSpA) and examines whether stricter screening rules for
LTBI, with subsequent INH treatment when indicated,
can reduce the risk of reactivation of TB in CZP-treated
patients. The effects of baseline PPD status or different
geographic regions on the IR of TB were also evaluated.
METHODS
Patient population and study designs
For RA, the pooled CZP safety database included 4049
patients with RA from 14 studies (including randomised
controlled trials (RCTs) and open label extensions
(OLEs); figure 2A), with maximum CZP exposure of
7.6 years as previously described.21 The first patient was
enrolled by the end of 1998 and the safety cut-off date was
30 November 2011. Safety data were also assessed in 528
patients with RA enrolled in two Japanese CZP RCTs and
their OLEs ( J-RAPID (NCT00791999, NCT00851318),
HIKARI (NCT00791921, NCT00850343)) from 19
November 2008 up to 6 June 2013 (figure 2B).
In addition, safety data were assessed for psoriasis phase
2 CZP studies conducted between October 2005 and May
2007 (N=117 patients; C87040 (NCT00245765) and
C87044 (NCT00329303)). Safety data were also assessed
for the RAPID-PsA15 (N=393 patients; NCT01087788) and
RAPID-axSpA18 studies (N=315 patients; NCT01087762)
initiated in March 2010, using the new TB screening
cut-off criteria of ≥5 mm induration for PPD positivity, up
to the cut-off date of 16 November 2012 (figure 2B).
For the majority of RA studies, and for RAPID-PsA and
RAPID-axSpA, a loading dose of CZP 400 mg was adminis-
tered subcutaneously at weeks 0, 2 and 4, followed by CZP
200 mg every 2 weeks (Q2W) or CZP 400 mg every
4 weeks (registered doses). During RAPID1 and RAPID2
RCTs (NCT00152386, NCT00160602), and for ≥6 months
during their OLEs (NCT00175877, NCT00160641), CZP
was also administered at 400 mg Q2W (twice the registered
dose) for all patients. Across trials, patients were exposed
to CZP either as a monotherapy or in combination with
methotrexate and/or other DMARDs.
TB screening and protocol amendment
All patients were screened for TB at study baseline. The
safety database was manually reviewed retrospectively by
independent experts ( JC, RvV, XM, KW, LC for RA; JC,
RvV, XM, KW, LC, JV, JG-R, MW, OL for psoriasis, PsA
and axSpA). All cases of suspected TB (PPD positive or
exhibiting signs/symptoms compatible with TB) were
classified as active TB, LTBI or PPD positive, or as non-
evaluable. Active TB cases reported in this paper were
confirmed according to the WHO or Centers for
Disease Control and Prevention (CDC) criteria for TB.22
In CZP studies before 2007, TB screening was con-
ducted according to respective national guidelines of
the recruiting study centre (cut-off for PPD positivity
ranged from ≥5 up to ≥20 mm). Since 2007, patients
were screened for PPD positivity ≥5 mm at baseline and
subsequently received INH treatment for LTBI if they
tested PPD positive. This amendment was also enforced
retrospectively for all patients already on CZP treatment
at the time of protocol amendment. Thus, patients with
a baseline PPD of ≥5 mm or no precise information on
the wheal size, and no evidence of TB infection, were
treated with INH for 9 months, regardless of prior
exposure to CZP.11 12 Patient TB questionnaires were
also administered every 6 months (figure 1).
Stratification of RA studies
Data from the pooled RA safety database21 (which
excluded the Japanese RA trials) were assessed for trials
initiated prior to 2007 (2367 patients) in two subgroups:
(1) original trials (837 patients), completed prior to TB
screening protocol amendment; and (2) intermediate
trials (1530 patients from the RAPID1 and RAPID2
trials), which were initiated using PPD positivity cut-off
from ≥5 to ≥20 mm but amended retrospectively. Group
(3), current trials (1682 patients), were initiated after
protocol amendment in 2007 and any patient was
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subsequently treated for LTBI if they tested PPD positive
at study baseline.
Statistical analyses
Safety assessments included all confirmed TB events that
occurred after the first dose of CZP or placebo (PBO),
and up to 84 days after the last study dose or patient
withdrawal. Total exposure to CZP, as used in the IR cal-
culation, was defined as the time from the first dose
until the date that the TB event was reported.
Exposure-adjusted IRs per 100 patient-years (PY), with
95% CI, are presented in this analysis. In some
instances, data are also presented as the percentage of
patients with events divided by the total number of
patients. All statistics were performed using SAS V.9.1 or
a later version.
RESULTS
Incidence of TB in CZP-treated patients across indications
The incidence of TB was assessed in a total of 5402 CZP
patients treated for RA, psoriasis, PsA and axSpA, with
Figure 1 Evaluation for signs and symptoms of the tuberculosis (TB) questionnaire (sample).
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an overall IR of 0.42/100 PY (95% CI 0.31 to 0.57). For
RA, 4049 patients were included in the pooled safety
database (9277 PY; mean CZP exposure 782 days,
median exposure 267 days).21 Up to 30 November 2011,
44 confirmed TB cases were reported in CZP-treated
patients with RA (IR 0.47/100 PY (0.34 to 0.64); also,
there were 30 cases of pulmonary TB and 14 cases of
non-pulmonary (including isolated lymph node TB) or
disseminated TB (occurring in two or more non-
continuous organs)). No TB cases were reported in PBO
patients during RCTs; however, the total exposure time
was relatively short (total exposure 373 PY; mean expos-
ure 110 days), mainly due to mandatory early escape to
active CZP treatment for non-responders at weeks 12
and 14 in the RAPID1 and RAPID2 studies, as compared
to CZP exposure (total exposure 9277 PY; mean expos-
ure 782 days). Separate analysis of safety data from 528
patients with RA enrolled in Japanese CZP trials
( J-RAPID and HIKARI and their OLEs) conducted up
to 6 June 2013 confirmed no cases of TB (figure 3).
Incidence of TB was also assessed in 117 study patients
with psoriasis (85 PY; mean CZP exposure 206 days) up
to 9 May 2007 and confirmed one case of disseminated
TB after 61 days of CZP exposure (IR 1.18/100 PY (0.03
to 6.58)). The incidence of TB was also assessed in 393
RAPID-PsA patients (612 PY; mean CZP exposure
Figure 2 Study design of CZP trials included in the safety analysis for the incidence of tuberculosis (TB). CZP, certolizumab
pegol; OLE, open label extensions; RA, rheumatoid arthritis;
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568 days) and 315 RAPID-axSpA patients (481 PY; mean
CZP exposure 558 days). Up to 16 November 2012, a
single case of pulmonary TB was confirmed in
RAPID-axSpA (IR 0.21/100 PY (0.01 to 1.15)), with no
confirmed cases in RAPID-PsA.
Incidence of TB in patients with RA by protocol period
and duration of TB exposure
Overall, the IR of TB in CZP-treated patients with RA in
trials initiated prior to protocol amendment was 0.51/
100 PY (0.37 to 0.69) (42/2367 patients); 2.63/100 PY
(1.61 to 4.06) in original trials (20/837 patients) and
0.30/100 PY (0.19 to 0.45) in intermediate trials spanning
the period of protocol amendment (22/1530 patients).
For current trials initiated with the standardised 5 mm
PPD cut-off after protocol amendment was enforced, the
IR was 0.18/100 PY (0.02 to 0.66) (2/1682 patients). In
total, 11/44 TB cases in RA trials were diagnosed after
protocol amendment (9 from intermediate trials [RAPID1
and RAPID2] and 2 from current trials; figures 3 and 4).
Of these 11 TB cases, 10 patients were considered PPD
negative at baseline (PPD<5 mm) and one patient had an
unknown PPD value. All nine patients from the intermedi-
ate period had PPD<5 mm at baseline and were from
Central or Eastern Europe, with TB onset occurring
≥718 days after the first dose of CZP. Of the confirmed
Figure 3 Summary of TB cases across indications and trial periods. †A total of 42 TB cases were reported in rheumatoid
arthritis (RA) trials initiated or completed prior to protocol amendment; 20 cases in original RA trials (completed prior to protocol
amendment) and 22 in intermediate RA trials (initiated before but completed after the introduction of more stringent PPD
screening criteria in 2007). *Of the 22 TB cases in patients with RA from intermediate RA trials (RAPID1 and RAPID2), 9 cases
were reported after protocol amendment. AxSpA, axial spondyloarthritis; PsA, psoriatic arthritis; IR, incidence rates; PY,
patient-years; TB, tuberculosis.
Figure 4 Cumulative incidence
of tuberculosis (TB) in
certolizumab pegol (CZP)-treated
patients with rheumatoid arthritis
(RA) in the pooled RA safety
database (N=4049) in relation to
study year. Cumulative incidence
of TB in RA trials between 1998
and the safety data-cut in
November 2011. The cumulative
number of recruited patients in
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TB cases in patients with RA, 21/44 were reported during
the first year of CZP exposure. This included both cases
of TB in current RA CZP trials, reported in patients with
either negative or unknown baseline PPD test values.
Incidence of TB in relation to baseline PPD status and INH
treatment for LTBI
A total of 370/4049 patients in the pooled RA safety data-
base had baseline PPD ≥5 mm. Of these, 242 patients
received treatment for LTBI (figure 5); 27 began INH
treatment prebaseline, 15 at study baseline, and 200
patients started treatment for LTBI postbaseline following
the protocol amendment. No PPD positive patients with
RA in receipt of INH treatment for 9 months developed
TB (figure 5). One hundred twenty eight patients did
not receive INH treatment as they were considered PPD
negative according to local guidelines at the time of study
enrolment, or had no symptoms of active TB. Of these,
10 patients recruited prior to protocol amendment went
on to develop TB. According to the stricter guidelines for
PPD positivity cut-off, these patients would have been
considered PPD positive at the time of screening. Four
had a PPD test result of 5–10 mm and the remaining six
patients had baseline PPD >10 mm (table 1). The average
time of TB onset after the first dose of CZP was between
∼1 and 1.5 years, and 6/10 cases were isolated pulmonary
TB (table 1).
A total of 3278 patients had a PPD<5 mm and were con-
sidered PPD negative; the remaining 401 patients had no
PPD test values recorded. Among patients with
baseline PPD<5 mm, INH treatment (typically adminis-
tered postbaseline) had little impact on TB incidence;
1/126 INH-treated patients (0.8%) versus 31/3152
non-INH-treated patients (1.0%) developed TB
(figure 5). INH treatment of the PPD negative patient
who went on to develop TB was initiated following a posi-
tive routine QuantiFERON test, performed 393 days after
starting CZP treatment, and TB was reported 517 days
later. The average time to TB onset in the 32 patients
with PPD<5 mm at baseline was ∼1.5 years after the first
dose of CZP, the long latency suggestive of a new TB
infection rather than LTBI reactivation. The majority of
cases (22/32) were diagnosed as isolated pulmonary TB
(table 1). Onset of TB in the two patients with RA with
unknown PPD value occurred 142 and 200 days after the
first dose of CZP; one patient had a history of positive
PPD tests and was treated with INH for 141 days prior to
administration of CZP, suggesting reactivation of LTBI.
Figure 5 PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence
by INH treatment. †One patient who developed TB started INH treatment 393 days after the first CZP dose was administered.
INH was administered from 517 to 251 days before TB was diagnosed. CZP, certolizumab pegol; PPD, purified protein derivative;
INH, isoniazid; RA, rheumatoid arthritis; TB, tuberculosis.
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In the J-RAPID/HIKARI trials, 213/528 patients
received INH at study baseline (no cases of TB were
reported in these trials). No INH treatment for LTBI
was administered to patients enrolled in psoriasis CZP
trials (study 040/044), including a patient who devel-
oped disseminated TB. In the RAPID-PsA and
RAPID-axSpA trials, a total of 26/393 and 25/315
patients, respectively, received INH treatment at study
baseline. The single case of pulmonary TB reported in
the RAPID-axSpA trial occurred in a PPD negative
patient who did not receive treatment for LTBI. Onset
of TB in the patient with axSpA, originally randomised
to PBO for 24 weeks, was reported after 170 days of CZP
exposure.
Overall, of the 46 cases of confirmed TB across CZP
trials (44 in RA (20 in original, 22 in intermediate and 2 in
current trials), 1 in psoriasis, 1 in axSpA), 34 were
observed prior to the implementation of stricter screen-
ing rules (33 in RA, 1 in psoriasis) and predominantly
occurred in patients who did not receive INH treatment.
Incidence of TB in relation to geographic location
The geographic distribution of CZP-treated patients in
the pooled RA safety database was 19.8% from Western
Europe, 20.0% from Central Europe, 12.4% from
Eastern Europe, 41.3% from North America and 6.5%
from the Rest of the World. United Nations statistics for
the lower bound incidence of TB in the general popula-
tion report a higher risk in Eastern and Central Europe
(table 2). Consistent with this, the majority of TB cases
observed with CZP originated in Eastern Europe (21
cases; IR 1.02/100 PY (0.63 to 1.56)) and Central
Europe (18 cases; IR 0.58/100 PY (0.34 to 0.92)). 29/32
TB cases in patients with RA with PPD<5 mm at baseline
were reported in patients from Eastern or Central
Europe. Nevertheless, the rate of TB in patients with RA
was far below the expected rate observed in the general
population in each respective country (table 2). Three
TB cases were confirmed in Western Europe (2 in
Germany, 1 in the UK) along with single cases in North
America (US) and the Rest of the World (Argentina)
(table 2). The single cases of TB in the psoriasis and
axSpA trials were in France and Argentina, respectively.
Of note, for current RA trials, the number of patients
recruited from Central Europe and Eastern Europe was
0 and 40 patients, respectively, and may have contributed
to the reduced rates of TB observed in patients with RA
after protocol amendment. The majority of patients with
RA in current trials were recruited from North America
(1319/1682 patients).
DISCUSSION
Since the introduction of stricter screening rules for
LTBI in CZP clinical trials (cut-off for PPD positivity of
≥5 mm and a TB questionnaire including 13 questions
relating to symptoms and risk factors for TB, in addition
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9 months in patients at risk, the IR of TB infection in
CZP-treated patients with RA has decreased from 2.63/
100 PY (original trials) to 0.18/100 PY (current trials).
This rate is comparable to that reported for other mono-
clonal anti-TNF antibodies (IR ∼0.3/100 PY)23–25 and
suggests beneficial effects of stricter LTBI screening
prior to administering anti-TNFs in patients with IMID.
A similar IR of 0.21/100 PY was reported for CZP-
treated RAPID-axSpA patients (1 case), with no TB cases
in RAPID-PsA patients to date.
Previous reports suggest that the risk of TB is elevated
∼2− to 4-fold in patients with RA compared to the
general population6 7 and that it further increased
1.6–25.1 times following anti-TNF therapy. 1 3 6 26 Over
the past decade, there are signs of a global decrease in
TB incidence among patients with anti-TNF,5 but the IRs
in some areas (eg, large cities) remain higher than the
national rates.27 Furthermore, the overall risk of TB may
depend on many factors including the population
exposed, clinical setting, comorbidities, concomitant
medications and anti-TNF administered. Studies suggest
that the majority of TB cases which develop soon after
initiation of anti-TNF treatment are due to reactivation
of LTBI.2 3 For CZP trials: 21/44 TB cases in patients
with RA and two confirmed cases in patients with psoria-
sis and axSpA were reported during the first year of CZP
treatment; implying that the cases were most likely due
to reactivation of LTBI despite PPD negativity (<5 mm)
at baseline, whereas in patients with onset of TB >1 year
after the start of CZP therapy, yet testing PPD negative at
baseline, it is likely to be a new TB infection.2 17 No new
cases of TB were reported in those who received INH as
a result of a positive tuberculin skin test (PPD≥5 mm),
emphasising the benefits of more stringent screening of
patients for LTBI and administration of LTBI therapy,
regardless of vaccination status. Only two patients
received INH treatment prior to TB diagnosis. The
lower IR of TB in intermediate trials compared with
original trials (0.30/100 PY vs 2.63/100 PY) suggests
beneficial effects of treatment for LTBI in patients on
long-term CZP treatment, even when administered
sometime after the start of anti-TNF therapy. In current
trials, recruitment of fewer patients from high TB inci-
dence countries, changes in study design, introduction
of a 6-monthly TB questionnaire to increase patient/
physician awareness (and facilitate appropriate manage-
ment of TB) and recruitment of fewer biologically naïve
patients5 are likely to have contributed to reduced TB
rates. During this study, only INH monotherapy was used
for treatment of LTBI. However, no specific compliance
check for patient adherence to 9 months of INH treat-
ment was performed. The shorter regimen of INH and
Rifampicin dual therapy (typically 3 months) was not
used, even though this approach is associated with
better treatment compliance.
The majority of TB cases in RA were reported from
Central and Eastern Europe, consistent with the higher
notification rates and risk of TB in these regions.27 28
A high proportion of these patients were PPD negative,
in line with lower rates of PPD positivity than TB rates in
TB endemic countries and high anergy rates for TB
screening in patients with severe inflammatory diseases.29
Glucocorticoid treatment may also lead to false negative
PPD skin test results,28 potentially resulting in inadequate
LTBI treatment of at-risk patients. In contrast, prior BCG
vaccination, sensitisation resulting from infection with
environmental mycobacteria or an increase in non-TB
mycobacteria may generate false positive test results.1 30
Nevertheless, in most cases, routine BCG vaccination in
newborns in TB endemic countries is unlikely to account
for positive PPD skin tests during adulthood as reactivity
declines during early childhood.31 32 Consequently, fre-
quent monitoring of patients in TB endemic countries
may be required. Repeated PPD tuberculin skin tests are
one approach, but potential booster effects could limit
the interpretation of results.
In vitro interferon-γ release assays (IGRAs; ie,
QuantiFERON Gold or ELISPOT TB) data may provide
an alternative LTBI screening method with improved
specificity in BCG-vaccinated patients, reducing unneces-
sary administration of INH treatment for LTBI and its
associated risks.33–35 Although IGRAs can provide
improved specificity,33 34 they can also produce false
positives.34 Thus, reliance on a single screening test is
not without problems and, in high TB endemic areas,
the use of algorithms that combine the results of dual
testing (PPD skin test and IGRAs) may provide greater
benefits.35 36 The lack of a gold standard for identifying
BK infections does not allow an optimal evaluation of
any TB screening method. In countries with low TB inci-
dence or where BCG vaccination is generalised, using
both tests may lead to an overuse of treatment for LTBI
and use of IGRAs alone should be encouraged.18 33 One
limitation of the present paper is the lack of concomi-
tant IGRAs data, not available at the start of the CZP
programme.
A comparison of TB incidence in CZP trials with find-
ings from other anti-TNF trials is limited by different
inclusion/exclusion criteria, trial locations and other
risk factors. Moreover, prior to the recent introduction
of a specific Medical Dictionary for Regulatory Activities
(MedDRA) preferred term for TB,37 different sponsors
may have reported positive PPD test results (LTBI),
suspected TB or confirmed TB as a TB event.23 38 39
A recent meta-analysis assessing the risk of TB in
patients with IMID treated with biologicals or tofacitinib
reported elevated TB rates across trials, with higher rates
for CZP.40 However, inclusion of suspected or LTBI cases
from CZP trials and the recruitment of patients from
high TB incidence countries is likely to have contributed
to this finding. In general, data on the IR of TB from
biological clinical trials that enrol patients from TB
endemic countries are limited.40 In CZP trials, non-TB
mycobacteria may also be a confounding factor, but spe-
cific diagnostic tools allowing systematic screening are
missing and no non-TB mycobacteria cases were
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identified by the investigators. For the soluble
TNF-receptor agent, reports evidenced a lower TB inci-
dence,1 2 consistent with less stable inhibition of
membrane-bound TNF and reduced effectiveness in the
treatment of granulomatous inflammatory conditions
such as Crohn’s disease.
In summary, methods of screening for LTBI and deci-
sions on whether to administer INH therapy can influ-
ence the incidence of TB in anti-TNF patients. In CZP
trials, several cases of TB occurred in patients with nega-
tive PPD (<5 mm) at screening who did not receive INH
treatment. However, the likelihood of developing TB was
greatest in those with PPD ≥5 mm who did not receive
treatment for LTBI. Physicians should be aware of the
importance of adequate TB screening for biologicals
patients, particularly in TB endemic countries and in
discrete high TB incidence regions of countries with
relatively low national TB rates. Increasing the stringency
of TB assessments (eg, PPD positivity cut-off of ≥5 mm
induration irrespective of vaccination status, alongside
repeated/alternative screening tests) may reduce TB
incidence in patients treated with anti-TNF and enable
those receiving treatment for LTBI to continue bio-
logical therapy for their chronic autoimmune disease.
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